Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Reshuffles Management in Advance of Danaher Acquisition

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – With the sale of Beckman Coulter to Danaher expected to close later this month, Beckman today disclosed a reshuffling of its management.

In a document filed with the US Securities and Exchange Commission, the Brea, Calif.-based company said that J. Robert Hurley will continue as president and CEO while also assuming responsibilities as interim Diagnostic Division President. Scott Atkin, formerly executive vice president of chemistry, discovery, and instrument systems development, was named president of the Life Science Division, effective June 6.

Following a transition period after the closing of the sale to Danaher, Beckman's Senior Vice President and CFO Charles Slacik's employment will end, Beckman said. Also, the employment of Arnold Pinkston, senior vice president and general counsel, and Robert Kleinert, executive vice president of worldwide commercial operations, will end following the closing of the deal.

At the Jefferies Global Healthcare Conference earlier this week in New York, Danaher CEO Larry Culp said that his firm anticipates its $6.8 billion acquisition of Beckman will close by the end of the month.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.